Vor Biopharma Q1 2024 GAAP EPS $(0.45) Misses $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vor Biopharma (NASDAQ:VOR) reported a Q1 2024 GAAP EPS loss of $(0.45), missing the consensus estimate of $(0.37) by 21.62%.
May 09, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vor Biopharma reported a Q1 2024 GAAP EPS loss of $(0.45), missing the consensus estimate of $(0.37) by 21.62%.
Missing the consensus estimate by 21.62% is significant and typically leads to negative investor sentiment in the short term. This earnings miss could lead to a decrease in stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100